Company intelligence / Profile preview
Translational Sciences, Inc.
Paradise Valley, Arizona, United Statestranslationalsciences.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Their lead drug TS23 shows promise in dissolving blood clots and aneurisms that could cause strokes. The company signed an exclusive licensing agreement with CSL, a leading global biotechnology company, for TS23.
- Therapeutic areas
- HematologyCardiovascular
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CSL (exclusive licensing agreement for TS23)
Beyond the preview
Go deeper on Translational Sciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Translational Sciences, Inc..